Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abbott
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Meet criteria for attention-deficit/hyperactivity disorder
Have voluntarily signed an informed form
Are between 18 and 60 years of age
Will use contraceptive methods during the study
Women must not be pregnant or breast-feeding
Must be in generally good health
Are fluent in English
You may not be if
They have a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder or mental retardation
They have a current diagnosis of major depressive episode, generalized anxiety disorder (GAD), or post-traumatic stress disorder (PTSD) or has a clinically significant sleep disorder requiring treatment
They require ongoing treatment or expected treatment with any psychotropic medication, including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood stabilizers, nicotine replacement therapies or varenicline
They require ongoing treatment or expected treatment with Coumadin
They failed to respond to two or more adequate trials of FDA-approved ADHD medication
They have taken atomoxetine during the last 3 months
They have violent, homicidal or suicidal ideation
They have a significant history of medical diagnoses, seizure disorder, Tourette's syndrome, traumatic brain injury, or a central nervous system (CNS) disease, excluding ADHD
They have a urine drug screen that is positive for alcohol or drugs of abuse
They have a history of substance or alcohol disorder during the last 3 months
Clareo Health | A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
